Concepedia

Author

Cynthia Huang Bartlett

Pfizer (United States)ORCID

Also Known As

C Bartlett, C. Bartlett, C. Huang Bartlett, C. Huang-Bartlett, C.H. Bartlett, C.H.u.a.n.g. Bartlett, Cynthia Bartlett, Cynthia H Bartlett, Cynthia H. Bartlett, Cynthia Huang Bartlett

121

Publications

11.4K

Citations

36

H-Index

59

Concepts

All Affiliations

Pfizer (United States)Royal Marsden HospitalInstitute of Cancer ResearchPeter MacCallum Cancer CentreInstitut Gustave Roussy
CH

About

Cynthia Huang Bartlett is an author at Pfizer (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

23

2.6K

2

Health Sciences

10

10

1.9K

3

Cell Biology

2

2

44

4

Diagnostic Sciences

1

1

29

5

Hepatology

1

1

18

Cynthia Huang Bartlett

×

55

Publications

10.8K

Citations

33

H-Index

YearCitations

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko,

The Lancet Oncology

2016

1.8K

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André,

New England Journal of Medicine

2015

1.5K

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro,

New England Journal of Medicine

2018

1.2K

Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

Charlotte Fribbens, Ben O’Leary, Lucy Kilburn,

Journal of Clinical Oncology

2016

696

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

Ben O’Leary, Rosalind Cutts, Yuan Liu,

Cancer Discovery

2018

642

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

Nicholas C. Turner, Yuan Liu, Zhou Zhu,

Journal of Clinical Oncology

2019

435

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Hope S. Rugo, Richard S. Finn, Véronique Dièras,

Breast Cancer Research and Treatment

2019

415

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Ben O’Leary, Sarah Hrebien, James P. Morden,

Nature Communications

2018

404

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Feng Gao, Jingqin Luo,

Clinical Cancer Research

2017

359

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín,

The Lancet Oncology

2021

250

Page 1